Healthcare / BiotechnologyNYSE
$1.82
-0.10 (-5.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-25.6M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$77M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-171.2%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-28.9M · FCF $-25.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | — | — | — | — | — | $0.00 | $0.00 | — |
| Net Income | $-28.9M | $-28.9M | $-24.6M | $-56.2M | $-25.3M | $-14.5M | $-5.5M | $-990980.00 |
| EBITDA | $-29.7M | $-29.7M | $-26.7M | $-45.0M | $-25.5M | — | — | — |
| EPS | — | — | -2.31 | -6.23 | -3.10 | -1.90 | -0.87 | — |
| Balance Sheet | ||||||||
| Current Ratio | 5.80 | 5.80 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-25.6M | $-25.6M | $-21.9M | $-40.0M | $-17.3M | — | — | — |
| Returns | ||||||||
| ROE | -171.2% | -171.2% | -264.2% | 725.1% | -89.4% | -32.6% | -72.4% | 11.6% |
| Valuation | ||||||||
| P/B | 2.94 | 2.94 | 7.09 | — | 3.80 | — | — | — |
| Growth & Yield | ||||||||
| EPS Growth | — | — | 62.9% | -101.0% | — | -118.4% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.31 → n/d
Residual
-22.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.